Natixis Bio Techne Corp Transaction History

Natixis

$16 Billion
Q4 2024

A detailed history of Natixis transactions in Bio Techne Corp stock. As of the latest transaction made, Natixis holds 10,412 shares of TECH stock, worth $685,109. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,412

Holding current value

$685,109

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$66.37 - $78.17 $691,044 - $813,906	10,412 New	10,412 $749,000
Q2 2024 Aug 13, 2024	BUY	$62.12 - $84.15 $918,692 - $1.24 Million	14,789 New	14,789 $1.06 Million
Q4 2023 Feb 13, 2024	BUY	$52.83 - $78.22 $888,759 - $1.32 Million	16,823 New	16,823 $1.3 Million
Q4 2022 Feb 24, 2023	SELL	$80.67 - $352.29 $3.05 Million - $13.3 Million	-37,803 Reduced 97.05%	1,150 $95,000
Q4 2022 Feb 13, 2023	BUY	$80.67 - $352.29 $2.84 Million - $12.4 Million	35,208 Added 940.13%	38,953 $3.23 Million
Q3 2022 Nov 14, 2022	BUY	$282.54 - $391.85 $203,711 - $282,523	721 Added 23.84%	3,745 $1.07 Million
Q2 2022 Aug 12, 2022	BUY	$322.67 - $449.65 $975,754 - $1.36 Million	3,024 New	3,024 $1.05 Million
Q4 2021 Feb 14, 2022	SELL	$456.15 - $525.06 $495,835 - $570,740	-1,087 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$444.87 - $538.88 $130,346 - $157,891	293 Added 36.9%	1,087 $527,000
Q2 2021 Aug 13, 2021	SELL	$387.35 - $450.26 $1.86 Million - $2.16 Million	-4,806 Reduced 85.82%	794 $358,000
Q1 2021 May 14, 2021	SELL	$314.62 - $411.0 $4.66 Million - $6.08 Million	-14,805 Reduced 72.56%	5,600 $2.14 Million
Q2 2019 Aug 13, 2019	BUY	$188.72 - $215.43 $1.29 Million - $1.47 Million	6,845 Added 50.48%	20,405 $4.25 Million
Q1 2019 May 15, 2019	BUY	$136.09 - $200.44 $1.85 Million - $2.72 Million	13,560 New	13,560 $2.67 Million

Others Institutions Holding TECH

# of Institutions

615

Shares Held

156M

Call Options Held

161K

Put Options Held

12.7K

View Full List

About BIO-TECHNE Corp

Ticker TECH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,222,600
Market Cap $2.58B
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures bi...

More about TECH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account